Published online Sep 6, 2024. doi: 10.12998/wjcc.v12.i25.5749
Revised: June 27, 2024
Accepted: July 3, 2024
Published online: September 6, 2024
Processing time: 56 Days and 16.1 Hours
The prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with chronic hepatitis B (CHB) has increased in recent clinical practice; however, the relationship between CHB and hepatic steatosis (HS) remains controversial.
To shed light on the potential association between NAFLD and hepatitis B virus (HBV) infection.
We conducted a systematic literature search using multiple databases, including PubMed, the Cochrane Library, Web of Science, and EMBASE, to identify relevant studies. Predefined inclusion criteria were used to determine the eligibility of the studies for further analysis.
Comprehensive meta-analysis software was used for statistical analysis, which covered 20 studies. The results indicated a lower NAFLD susceptibility in HBV-infected individuals (pooled OR = 0.87; 95%CI = 0.69-1.08; I2 = 91.1%), with diabetes (P = 0.015), body mass index (BMI; P = 0.010), and possibly age (P = 0.061) as heterogeneity sources. Of note, in four studies (6197 HBV patients), HBV-infected individuals had a reduced NAFLD risk (OR = 0.68, 95%CI = 0.51-0.89, P = 0.006). A positive link between hyperlipidemia and metabolic syndrome emerged in hepatitis B patients, along with specific biochemical indicators, including BMI, creatinine, uric acid, fasting blood glucose, and homeostasis model assessment of insulin resistance.
HBV infection may provide protection against HS; however, the occurrence of HS in patients with HBV infection is associated with metabolic syndrome and specific biochemical parameters.
Core Tip: Investigating chronic hepatitis B (CHB) and nonalcoholic fatty liver disease (NAFLD) was reviewed in 20 studies. The results suggest reduced NAFLD susceptibility in hepatitis B virus (HBV)-infected individuals (OR = 0.87, 95%CI = 0.69-1.08, I2 = 91.1%). In HBV patients, a positive correlation emerged between hyperlipidemia, metabolic syndrome, and indicators, such as body mass index, creatinine, uric acid, fasting blood glucose, and homeostasis model assessment of insulin resistance. HBV may protect from hepatic steatosis, but its occurrence is associated with metabolic syndrome and specific factors. This study describes the complex interplay between CHB, NAFLD, and its associated factors.